DrugPatentWatch Database Preview
LUCEMYRA Drug Profile
When do Lucemyra patents expire, and when can generic versions of Lucemyra launch?
Lucemyra is a drug marketed by Us Worldmeds Llc and is included in one NDA.
The generic ingredient in LUCEMYRA is lofexidine hydrochloride. One supplier is listed for this compound. Additional details are available on the lofexidine hydrochloride profile page.
Summary for LUCEMYRA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 43 |
| Clinical Trials: | 3 |
| Patent Applications: | 855 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for LUCEMYRA |
| DailyMed Link: | LUCEMYRA at DailyMed |
Generic Entry Opportunity Date for LUCEMYRA
Generic Entry Date for LUCEMYRA*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for LUCEMYRA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| US WorldMeds LLC | Phase 2 |
| Frances R Levin | Phase 2 |
| Medical University of South Carolina | Phase 2 |
Synonyms for LUCEMYRA
| (-)-2-[1-(2,6-dichlorophenoxy)-ethyl]-1,3-diazacyclopent-2-ene |
| (+)-2-[1-(2,6-dichlorophenoxy)-ethyl]-1,3-diazacyclopent-2-ene |
| (S)-Lofexidine |
| 1H-Imidazole, 2-(1-(2,6-dichlorophenoxy)ethyl)-4,5-dihydro- |
| 1H-Imidazole, 2-(1-(2,6-dichlorophenoxy)ethyl)-4,5-dihydro- (9CI) |
| 1H-Imidazole, 2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro- |
| 1H-Imidazole,2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro- |
| 2-(1-(2,6-Dichlorophenoxy)ethyl)-4,5-dihydro-1H-imidazole |
| 2-(a-(2,6-dichlorophenoxy)ethyl)2-imidazoline |
| 2-(alpha-(2,6-dichlorophenoxy)ethyl) delta-2-imidazoline |
| 2-(alpha-(2,6-Dichlorophenoxy)ethyl)2-imidazoline |
| 2-[1-(2,6-dichlorophenoxy)ethyl]-2-imidazoline |
| 2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro-1H-imidazole |
| 2-[1-[2,6-bis(chloranyl)phenoxy]ethyl]-4,5-dihydro-1H-imidazole |
| 2-{1-[(2,6-dichlorophenyl)oxy]ethyl}-4,5-dihydro-1H-imidazole |
| 2-Imidazoline 2-(1-(2,6-dichlorophenoxy)ethyl)- |
| 31036-80-3 |
| 98L088 |
| A820699 |
| AB00698543_08 |
| AB00698543_09 |
| AB00698543-05 |
| AB00698543-07 |
| AC1L1K1D |
| AC1Q3Q8L |
| AKOS015900265 |
| BDBM50019646 |
| Britlofex |
| C-16142 |
| CAS-31036-80-3 |
| CC-30019 |
| CCG-220521 |
| CHEBI:51368 |
| CHEMBL17860 |
| CS-0013650 |
| D08141 |
| DB04948 |
| DSSTox_CID_3221 |
| DSSTox_GSID_23221 |
| DSSTox_RID_97547 |
| DTXSID7023221 |
| FT-0627970 |
| GTPL9868 |
| HMS2090C03 |
| HMS3713J03 |
| HY-B1052A |
| IMI019 |
| J-507626 |
| KS-0000103S |
| KSMAGQUYOIHWFS-UHFFFAOYSA-N |
| Lofexidina |
| Lofexidina [INN-Spanish] |
| Lofexidine |
| Lofexidine (INN) |
| Lofexidine [INN:BAN] |
| Lofexidinum |
| Lofexidinum [INN-Latin] |
| LS-79612 |
| NCGC00271513-02 |
| RP29235 |
| SCHEMBL48960 |
| SR-01000763628 |
| SR-01000763628-3 |
| SR-01000763628-4 |
| Tox21_113963 |
| UI82K0T627 |
| UNII-UI82K0T627 |
US Patents and Regulatory Information for LUCEMYRA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Us Worldmeds Llc | LUCEMYRA | lofexidine hydrochloride | TABLET;ORAL | 209229-001 | May 16, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
